Saturday, July 11, 2026

Drug profile · INN

penpulimab

penpulimab is a programmed cell death protein 1 inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 3
News articles 1
Drug details — penpulimab

Quick answer

penpulimab is a programmed cell death protein 1 inhibitor.

Key facts

INN penpulimab
Mechanism Programmed cell death protein 1 inhibitor
Target Programmed cell death protein 1

Mechanism of action

Programmed cell death protein 1 inhibitor

Primary target: Programmed cell death protein 1

Approval history

Authority Status Date
NMPA clinical trials

Recent coverage

Pipeline programs

  1. 2021-SR-545 Phase 2 · First People's Hospital · Lymphoma, Large B-Cell, Diffuse
  2. anlotinib combined with penpulimab Phase 2 · First People's Hospital · Non-small Cell Lung Cancer
  3. Anlotinib hydrochloride,Penpulimab Phase 1 · First People's Hospital · Colorectal Cancer

Related & competitor drugs

  1. cemiplimab Antineoplastic and immunomodulating agents (L01)
  2. cemiplimab-rwlc Programmed cell death protein 1 inhibitor
  3. tislelizumab Antineoplastic and immunomodulating agents (L01)
  4. toripalimab-tpzi Programmed cell death protein 1 antagonist
  5. dostarlimab-gxly Programmed cell death protein 1 antagonist
  6. islelizumab-jsgr Programmed cell death protein 1 inhibitor

Frequently asked questions

What is penpulimab?

penpulimab is a programmed cell death protein 1 inhibitor.